Comment: Fundamentals and Innovation in Antibiotic Trials
about
Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis.Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae.Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?
P2860
Comment: Fundamentals and Innovation in Antibiotic Trials
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comment: Fundamentals and Innovation in Antibiotic Trials
@en
type
label
Comment: Fundamentals and Innovation in Antibiotic Trials
@en
prefLabel
Comment: Fundamentals and Innovation in Antibiotic Trials
@en
P2860
P1476
Comment: Fundamentals and Innovation in Antibiotic Trials
@en
P2093
Dean Follmann
Scott R Evans
P2860
P304
P356
10.1080/19466315.2015.1094406
P577
2015-12-17T00:00:00Z